PT932402E - Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia - Google Patents
Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasiaInfo
- Publication number
- PT932402E PT932402E PT97911746T PT97911746T PT932402E PT 932402 E PT932402 E PT 932402E PT 97911746 T PT97911746 T PT 97911746T PT 97911746 T PT97911746 T PT 97911746T PT 932402 E PT932402 E PT 932402E
- Authority
- PT
- Portugal
- Prior art keywords
- neoplasia
- treatment
- prevencaode
- cyclooxygenase
- inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2849496P | 1996-10-15 | 1996-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT932402E true PT932402E (pt) | 2004-11-30 |
Family
ID=21843754
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04011516T PT1479385E (pt) | 1996-10-15 | 1997-10-14 | Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias |
| PT97911746T PT932402E (pt) | 1996-10-15 | 1997-10-14 | Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04011516T PT1479385E (pt) | 1996-10-15 | 1997-10-14 | Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias |
Country Status (24)
| Country | Link |
|---|---|
| EP (3) | EP1977749A1 (pt) |
| JP (1) | JP2001503395A (pt) |
| KR (1) | KR20000049138A (pt) |
| CN (2) | CN100558356C (pt) |
| AT (2) | ATE271385T1 (pt) |
| AU (1) | AU742645B2 (pt) |
| BR (1) | BR9712314A (pt) |
| CA (1) | CA2267186C (pt) |
| CZ (1) | CZ298022B6 (pt) |
| DE (2) | DE69738815D1 (pt) |
| DK (2) | DK0932402T3 (pt) |
| ES (2) | ES2224222T3 (pt) |
| HU (1) | HU227564B1 (pt) |
| IL (3) | IL154501A0 (pt) |
| NO (1) | NO326822B1 (pt) |
| NZ (3) | NZ334921A (pt) |
| PT (2) | PT1479385E (pt) |
| RO (1) | RO120172B1 (pt) |
| RU (1) | RU2239429C2 (pt) |
| SK (1) | SK284788B6 (pt) |
| TR (1) | TR199900827T2 (pt) |
| TW (1) | TWI235060B (pt) |
| UA (1) | UA67732C2 (pt) |
| WO (1) | WO1998016227A1 (pt) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| AU5886296A (en) | 1995-06-02 | 1996-12-18 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| US6887893B1 (en) | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
| US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| US6727238B2 (en) | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| KR20010109275A (ko) * | 1998-12-23 | 2001-12-08 | 로저 에이. 윌리암스 | 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법 |
| US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
| DE60041808D1 (de) * | 1999-01-27 | 2009-04-30 | Cornell Res Foundation Inc | Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs |
| NZ515711A (en) * | 1999-06-24 | 2004-01-30 | Pharmacia Corp | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
| WO2001008693A2 (en) * | 1999-07-29 | 2001-02-08 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| EP1233769B1 (en) | 1999-11-22 | 2007-12-26 | SmithKline Beecham plc | Imidazole derivatives |
| AU3653301A (en) * | 2000-01-28 | 2001-08-07 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| US20020009421A1 (en) * | 2000-06-01 | 2002-01-24 | Wilder Karol J. | Therapy following skin injury from exposure to ultraviolet radiation |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| US7199137B2 (en) | 2000-09-21 | 2007-04-03 | Smithkline Beecham Plc | Imidazole derivatives as Raf kinase inhibitors |
| AU2002234165A1 (en) | 2000-11-03 | 2002-05-27 | Tularik, Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| WO2002089790A1 (en) * | 2001-05-03 | 2002-11-14 | Cornell Research Foundation, Inc. | Treatment of hpv caused diseases |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0119477D0 (en) | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| DK1441714T3 (da) * | 2001-10-25 | 2008-03-31 | Novartis Ag | Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor |
| FR2835433B1 (fr) * | 2002-02-01 | 2006-02-17 | Richard Lab M | Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2 |
| AU2003220180A1 (en) * | 2002-03-15 | 2003-09-29 | Pharmacia Corporation | Crystalline parecoxib sodium |
| TW200408621A (en) | 2002-04-08 | 2004-06-01 | Glaxo Group Ltd | Compounds |
| EP1546128B1 (en) | 2002-08-19 | 2006-05-03 | Glaxo Group Limited | Pyrimidine derivatives as selective cox-2 inhibitors |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| KR100484525B1 (ko) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| PE20040844A1 (es) | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
| US7705027B2 (en) * | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2006089177A2 (en) | 2005-02-17 | 2006-08-24 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
| ES2397085T3 (es) | 2005-03-08 | 2013-03-04 | Mitsui Norin Co., Ltd | Procedimientos y combinaciones de polifenol-coxib |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| CN102089303A (zh) * | 2008-07-17 | 2011-06-08 | 旭化成制药株式会社 | 含氮杂环化合物 |
| CN102197144A (zh) * | 2008-08-22 | 2011-09-21 | 诺瓦提斯公司 | Cox-2抑制剂用于治疗不携带与肝脏毒性相关的hla等位基因的患者中cox-2依赖性疾病的用途 |
| US10525040B2 (en) | 2015-06-29 | 2020-01-07 | Nantbio, Inc. | Compositions and methods of Rit1 inhibition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
| DE69129611T2 (de) * | 1990-08-20 | 1998-12-17 | Eisai Co., Ltd., Tokio/Tokyo | Sulfonamid-Derivate |
| JP3155552B2 (ja) | 1991-07-19 | 2001-04-09 | モンサント カンパニー | 超酸化物の不均斉変化に有効な触媒としての窒素含有−大環状リガンドのマンガン錯体 |
| US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| ES2111288T3 (es) | 1993-01-15 | 1998-03-01 | Searle & Co | Nuevos 3,4-diaril tiofenos y analogos de los mismos utiles como agentes antiinflamatorios. |
| US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
| WO1994026731A1 (en) | 1993-05-13 | 1994-11-24 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
| US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| RU2121997C1 (ru) * | 1993-09-10 | 1998-11-20 | Эйсай Ко., ЛТД | Производные 7-амино-1н-индола |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
| ES2180233T3 (es) * | 1993-11-30 | 2003-02-01 | Searle & Co | Pirazolil bencenosulfonamidas sustituidas para uso en el tratamiento de la inflamacion. |
| US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| JPH10504542A (ja) | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5739166A (en) | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
| US5686470A (en) | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US5596008A (en) | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| JP3267300B2 (ja) | 1995-02-13 | 2002-03-18 | ジー．ディー．サール アンド カンパニー | 炎症の治療のための置換イソオキサゾール |
| US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
| AU5886296A (en) * | 1995-06-02 | 1996-12-18 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors |
| EP0859779A4 (en) | 1995-08-31 | 2000-04-12 | Smithkline Beecham Corp | INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS |
| PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
-
1997
- 1997-10-14 EP EP08159064A patent/EP1977749A1/en not_active Withdrawn
- 1997-10-14 JP JP51859198A patent/JP2001503395A/ja not_active Ceased
- 1997-10-14 AU AU49048/97A patent/AU742645B2/en not_active Ceased
- 1997-10-14 DE DE69738815T patent/DE69738815D1/de not_active Expired - Lifetime
- 1997-10-14 DK DK97911746T patent/DK0932402T3/da active
- 1997-10-14 ES ES97911746T patent/ES2224222T3/es not_active Expired - Lifetime
- 1997-10-14 CN CNB2005100062282A patent/CN100558356C/zh not_active Expired - Fee Related
- 1997-10-14 IL IL15450197A patent/IL154501A0/xx not_active IP Right Cessation
- 1997-10-14 DK DK04011516T patent/DK1479385T3/da active
- 1997-10-14 CN CNB971987548A patent/CN1332661C/zh not_active Expired - Fee Related
- 1997-10-14 UA UA99052704A patent/UA67732C2/uk unknown
- 1997-10-14 CA CA002267186A patent/CA2267186C/en not_active Expired - Fee Related
- 1997-10-14 AT AT97911746T patent/ATE271385T1/de active
- 1997-10-14 KR KR1019990703225A patent/KR20000049138A/ko not_active Withdrawn
- 1997-10-14 AT AT04011516T patent/ATE399547T1/de active
- 1997-10-14 BR BR9712314-5A patent/BR9712314A/pt not_active Application Discontinuation
- 1997-10-14 RU RU99110192/15A patent/RU2239429C2/ru not_active IP Right Cessation
- 1997-10-14 DE DE69729946T patent/DE69729946T2/de not_active Expired - Lifetime
- 1997-10-14 NZ NZ334921A patent/NZ334921A/en not_active IP Right Cessation
- 1997-10-14 WO PCT/US1997/018670 patent/WO1998016227A1/en not_active Ceased
- 1997-10-14 TR TR1999/00827T patent/TR199900827T2/xx unknown
- 1997-10-14 EP EP97911746A patent/EP0932402B1/en not_active Expired - Lifetime
- 1997-10-14 TW TW090122228A patent/TWI235060B/zh not_active IP Right Cessation
- 1997-10-14 RO RO99-00418A patent/RO120172B1/ro unknown
- 1997-10-14 HU HU9904221A patent/HU227564B1/hu not_active IP Right Cessation
- 1997-10-14 ES ES04011516T patent/ES2308068T3/es not_active Expired - Lifetime
- 1997-10-14 CZ CZ0117199A patent/CZ298022B6/cs not_active IP Right Cessation
- 1997-10-14 IL IL12856897A patent/IL128568A0/xx not_active IP Right Cessation
- 1997-10-14 PT PT04011516T patent/PT1479385E/pt unknown
- 1997-10-14 EP EP04011516A patent/EP1479385B1/en not_active Expired - Lifetime
- 1997-10-14 NZ NZ506515A patent/NZ506515A/en not_active IP Right Cessation
- 1997-10-14 PT PT97911746T patent/PT932402E/pt unknown
- 1997-10-14 SK SK462-99A patent/SK284788B6/sk not_active IP Right Cessation
-
1999
- 1999-04-15 NO NO19991793A patent/NO326822B1/no not_active IP Right Cessation
-
2001
- 2001-02-07 NZ NZ509755A patent/NZ509755A/xx not_active IP Right Cessation
-
2004
- 2004-12-16 IL IL16581604A patent/IL165816A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT932402E (pt) | Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia | |
| EA200100572A1 (ru) | Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии | |
| EA199900137A1 (ru) | Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2 | |
| IL123002A0 (en) | 1-Phenyl-2- phenylacetoxy- ethanone derivatives | |
| BG101446A (bg) | Антинеопластични какаови екстракти, метод за получаване и използване | |
| DE69417012D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase | |
| PL326203A1 (en) | (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors | |
| MXPA02011425A (es) | Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa. | |
| DK1273299T3 (da) | Minoxidilinindeholdende praparater | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| DE69729183T2 (de) | Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen | |
| ATE297904T1 (de) | Halo-alkoxycarbonylverbindungen | |
| ATE223376T1 (de) | Bisarylcyclobutenderivate als cyclooxygenasehemmer | |
| ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
| DE59409456D1 (de) | Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien | |
| DK0996435T3 (da) | Aminosyrederivater anvendelige til behandling af slagtilfælde | |
| NO20032411D0 (no) | Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens | |
| ES2164454T3 (es) | Nuevos compuestos derivados de acido alquilendiamina di o tri-acetico, su procedimiento de preparacion, su utilizacion en composiciones cosmeticas y farmaceuticas y composiciones que los contienen. | |
| BR9710901A (pt) | M-todo para o tratamento da doen-a bipolar | |
| PT971714E (pt) | Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia | |
| HUP0002727A2 (hu) | Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával | |
| ATE228359T1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| DK0810223T3 (da) | Adamantylsubstituerede oxindoler som farmaceutiske midler |